Brookfield Corp’s BioNTech BNTX Stock Holding History

Brookfield Corp’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,371	Closed	-$1.41M	–	673
2022 Q4	$1.41M	Buy	+9,371	New	+$1.44M	0.01%	461

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.72B AUM 7.92% 1-Year Est. Return

Brookfield Corp's BNTX Position: Q1 2023 in Review

Brookfield Corp sold out of BioNTech (BNTX) in Q1 2023, closing a stake of 9,371 shares — an estimated $1.41M sold.

Brookfield Corp first reported a position in BNTX in Q4 2022 and held it in 1 quarter. The position peaked at $1.41M in Q4 2022. 281 funds tracked by Wall St. Rank hold BNTX as of Q1 2023.

Brookfield Corp reported no remaining BioNTech position as of Q1 2023 after selling out during the quarter.
Brookfield Corp sold 9,371 BioNTech shares in Q1 2023, an estimated $1.41M.
Brookfield Corp first reported a position in BioNTech in Q4 2022 and held it in 1 quarter.
Brookfield Corp's BioNTech position peaked at $1.41M in Q4 2022.
281 funds tracked by Wall St. Rank held BioNTech as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.